Target
everolimus
1 abstract
Abstract
Outcome of second-line treatment after CDK4/6 inhibitors in hormonal-positive HER-2 negative metastatic breast cancer: Single institution experience.Org: King Abdulla Medical City/Makkah, Oncology Center, Medica Sur Hospital, King Abdullah Medical City, Mansoura University, Medical Oncology Department, Presidio Ospedaliero Santa Maria della Misericordia, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy,